Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer

Annals of Oncology

Volumn 18, Issue 12, 2007, Pages 1943-1950

  Bijelic, L ^a   Jonson, A ^b   Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Cytoreductive surgery; Heat; Hyperthermia; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERFERON; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; THIOSULFATE;

BLOOD TOXICITY; CARCINOMATOUS PERITONITIS; CHEMOSURGERY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG FATALITY; HUMAN; LENGTH OF STAY; MONOTHERAPY; MORTALITY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; RENAL PROTECTION; REVIEW; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

EID: 34547976092     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm137     Document Type: Review

References (43)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334 (1): 1-6.
2. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354 (1): 34-43.
3. Markman M, Bundy BN, Alberts DS. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-1007.
4. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus-intravenous cyclophosphamide for stage III ovarian cancer. N Eng J Med 1996; 335: 1950-1955.
5. Zylberberg B, Dormont D, Madelenat P et al. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfomide in stage IIIc ovarian epithelial cancer. Eur J Gynaecol Oncol 2004; 25(3): 327-332.
6. Sugarbaker PH, New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncoll 2006; 7 (1): 69-76.
7. Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: Synergism between hyperthermia and adriamysin (or bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci U S A 1975; 172: 937-940.
8. NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying Out or Commissioning Reviews - CRD Report 4, 2nd edition. New York, UK: NHS Centre for Reviews and Dissemination 2001.
9. Rufian S, Munoz-Casares FC, Briceno J et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006; 94: 316-324.
10. Raspagliesi F, Kusamura S, Campos Torres JC et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006; 32(6): 671-675.
11. Reichman TW, Cracchiolo B, Sama J et al. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Sung Oncol 2005; 90: 51-58.
12. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanded and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004; 14: 35-41.
13. Piso P, Dahlke MH, Loss M et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg. Oncol 2004; 2: 21.
14. Zanon C, Clara R, Chiappino I et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Sung 2004; 28: 1040-1045.
15. Ryu KS, Kim JH, Ko HS et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 2004; 94: 325-332.
16. Chatzigeorgiou K, Economou S, Chrysafis G et al. Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHGP). Zentralbl Gynakol 2003; 125: 424-429.
17. DeBree E, Romanos J, Michalakis J et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin, Anticancer Res 2003; 23: 3019-3028.
18. Kecmanovic DM, Pavlov MJ, Kavacevic PA et al. Cytoreductive surgery for ovarian cancer, Eur J Surg Oncol 2003; 29: 315-320.
19. van der Vange N, van Goethern AR, Zoetmulder FAN et al. Extensive cytoreductive surgery combined with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: A feasibility pilot. Eur J Surg Oncol 2000; 26: 663-668.
20. Hadi R, Saunders V, Utkina O et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg 2006; 76: 156-161.
21. Fujimura T, Yunemura Y, Fujita H et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg 1999; 84: 60-66.
22. Kober F, Heiss A, Roka R. Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion. In Sugarbaker PH (ed): Peritoneal Carcinomatosis: Principles Of Management. Boston, MA: Kluwer Academic Publishers 1996; 211-219.
23. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patents with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15: 46-58.
24. Yan TD, Brun EA, Cerruto CA et al. Prognostic indicators for patient undergoing cytoreductive surgery and perloperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007; 14: 41-49.
25. Sugarbaker PH. Are there surgical options to peritoneal carcinomatosis? Ann Surg 2005; 242: 748-750.
26. Nonaka D, Kusamura S, Baratti D et al. Diffuse malignant mesotfielioma of the peritoneum: A clinicopathologic study of 35 patients treated locoregionally at a single institution. Cancer 2005; 104: 2181-2188.
27. Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2003; 21: 3737-3743.
28. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
29. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992; 166: 504-511.
30. Eisenkop SM, Friedman RL, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer. Cancer 1995; 76: 1606-1614.
31. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001; 83: 504-512.
32. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelia! ovarian carcinoma. Cancer 2000; 88: 144-153.
33. Flessner M, Lofthouse J, El Rashed Z. Improving contact area between peritoneum and intraperitoneal therapeutic solutions. J Am Soc Nephrol 2001; 12: 807-813.
34. Panteix G, Beaujard A, Garbit F et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002; 22: 1329-1336.
35. Orlando M, Huertas E, Salum G et al. Intraperitoneal hyperthermic chemotherapy as consolidation treatment for ovarian cancer In pathological complete remission. Proc Am Soc Clin Oncol 1998; 17: 372a (Abstr 1432).
36. Segna RA, Dottino PR, Scott Jennings T et al. Feasibility of intraoperative administration of chemotherapy for gynecologic malignancies: Assessment of acute postoperative morbidity. Gynecol Oncol 1993; 48: 227-231.
37. Hager ED, Dziambor H, Hohmann D et al. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001; 11 (Suppl 1): 57-63.
38. Steller MA, Egorin MJ, Trimble EL et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999; 43: 106-114.
39. Yoshida Y, Sasaki H, Kurokawa T et al. Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer:a long term follow-up. Oncol Rep 2005; 13: 121-125.
40. Gori J, Castano R, Toziano M et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005; 15: 233-239.
41. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
42. Sehouli J, Sommer H, Klare P et al. A randomized multicenter phase III trial of topotecan monotherapy versus topotecan+etoposide versus topotecan+gemcitabine for second-line treatment of recurrent ovarian cancer. J Clin Oncol 2006; 24(1BS): (Abstr 5030).
43. Sugarbaker PH, Torres Mora J, Carmignani P et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005; 10: 112-122.